Skip to main content
Elsevier
View Cart
openUserAccount

Books in Pharmaceutical science

BooksJournals
71-80 of 95 results in All results

Pharma's Prescription

  • 1st Edition
  • October 21, 2013
  • Kamal Biswas
  • English
  • eBook
    9 7 8 - 0 - 1 2 - 4 0 7 6 8 8 - 4
The pharmaceutical industry needs a shot in the arm – and not a moment too soon. The executive suite is mired in a bygone era, a time when extensive, well-funded pharmaceutical R&D produced blockbuster drugs, kept everything in-house and reaped the financial rewards. But that way of working needs to change. Executives now need to know what the technologists in their companies are doing in order to survive the next decade. Written for those new to industry, as well as for experienced professionals or specialists looking to expand their knowledge, this book is a must-read for business executives and information technologists alike. Pharma’s Prescription bridges the knowledge gap between current business practices and the most valuable technologies today. This book is filled with practical, real-life examples from industry and is a straightforward guide for all pharmaceutical and information technology executives who need to improve their businesses.

Formulation Tools for Pharmaceutical Development

  • 1st Edition
  • September 30, 2013
  • J E Aguilar
  • English
  • Hardback
    9 7 8 - 1 - 9 0 7 5 6 8 - 9 9 - 2
  • eBook
    9 7 8 - 1 - 9 0 8 8 1 8 - 5 0 - 8
A range of new and innovative tools used for preformulation and formulation of medicines help optimize pharmaceutical development projects. Such tools also assist with the performance evaluation of the pharmaceutical process, allowing any potential gaps to be identified. These tools can be applied in both basic research and industrial environment. Formulation tools for pharmaceutical development considers these key research and industrial tools.Nine chapters by leading contributors cover: Artificial neural networks technology to model, understand, and optimize drug formulations; ME_expert 2.0: a heuristic decision support system for microemulsions formulation development; Expert system for the development and formulation of push-pull osmotic pump tablets containing poorly water-soluble drugs; SeDeM Diagram: an expert system for preformulation, characterization and optimization of tables obtained by direct compression; New SeDeM-ODT expert system: an expert system for formulation of orodispersible tablets obtained by direct compression; and 3D-cellular automata in computer-aided design of pharmaceutical formulations: mathematical concept and F-CAD software.

The Path from Biomarker Discovery to Regulatory Qualification

  • 1st Edition
  • July 16, 2013
  • Federico Goodsaid + 1 more
  • English
  • Paperback
    9 7 8 - 0 - 1 2 - 3 9 1 4 9 6 - 5
  • eBook
    9 7 8 - 0 - 1 2 - 3 9 4 4 0 8 - 5
The Path from Biomarker Discovery to Regulatory Qualification is a unique guide that focuses on biomarker qualification, its history and current regulatory settings in both the US and abroad. This multi-contributed book provides a detailed look at the next step to developing biomarkers for clinical use and covers overall concepts, challenges, strategies and solutions based on the experiences of regulatory authorities and scientists. Members of the regulatory, pharmaceutical and biomarker development communities will benefit the most from using this book—it is a complete and practical guide to biomarker qualification, providing valuable insight to an ever-evolving and important area of regulatory science. For complimentary access to chapter 13, 'Classic' Biomarkers of Liver Injury, by John R. Senior, Associate Director for Science, Food and Drug Administration, Silver Spring, Maryland, USA, please visit the following site: http://tinyurl.com/ClassicBiomarkers

The Future of Drug Discovery

  • 1st Edition
  • May 18, 2013
  • Tamas Bartfai + 1 more
  • English
  • Paperback
    9 7 8 - 0 - 1 2 - 4 0 7 1 8 0 - 3
  • eBook
    9 7 8 - 0 - 1 2 - 4 0 9 5 1 9 - 9
The Future of Drug Discovery: Who decides which diseases to treat? provides a timely and detailed look at the efforts of the pharmaceutical industry and how they relate, or should relate, to societal needs. The authors posit that as a result of increasing risk aversion and accelerated savings in research and development, the industry is not developing drugs for increasingly prevalent diseases, such as Alzheimer’s disease, untreatable pain, antibiotics and more. This book carefully exposes the gap between the medicines and therapies we need and the current business path. By analyzing the situation and discussing prospects for the next decade, the The Future of Drug Discovery is a timely book for all those who care about the development needs for drugs for disease.

Profiles of Drug Substances, Excipients, and Related Methodology

  • 1st Edition
  • Volume 38
  • May 10, 2013
  • Harry G. Brittain
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 4 0 7 6 9 1 - 4
  • eBook
    9 7 8 - 0 - 1 2 - 4 0 7 8 2 8 - 4
Volumes in this widely revered series present comprehensive reviews of drug substances and additional materials, with critical review chapters that summarize information related to the characterization of drug substances and excipients. This organizational structure meets the needs of the pharmaceutical community and allows for the development of a timely vehicle for publishing review materials on this topic. The scope of the Profiles series encompasses review articles and database compilations that fall within one of the following six broad categories: Physical profiles of drug substances and excipients; Analytical profiles of drug substances and excipients; Drug metabolism and pharmacokinetic profiles of drug substances and excipients; Methodology related to the characterization of drug substances and excipients; Methods of chemical synthesis; and Reviews of the uses and applications for individual drug substances, classes of drug substances, or excipients.

Lead Compounds from Medicinal Plants for the Treatment of Cancer

  • 1st Edition
  • October 22, 2012
  • Christophe Wiart
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 3 9 8 3 7 1 - 8
  • eBook
    9 7 8 - 0 - 1 2 - 3 9 8 3 8 2 - 4
Lead Compounds from Medicinal Plants for the Treatment of Cancer is the first volume in the series, Pharmaceutical Leads from Medicinal Plants. The plant species described in this reference have been carefully selected based on pharmacological evidence and represent today’s most promising sources of natural products for the discovery of anti-cancer drugs. Containing references to primary source material, over a hundred botanical illustrations, a table of chemical structures and much more, this book is an essential starting point for cancer researchers and those involved in anti-cancer drug discovery helping you identify the best novel lead molecules for further anti-cancer drug development.

A Comprehensive Guide to Toxicology in Preclinical Drug Development

  • 1st Edition
  • October 18, 2012
  • Ali S. Faqi
  • English
  • eBook
    9 7 8 - 0 - 1 2 - 3 8 7 8 1 6 - 8
A Comprehensive Guide to Toxicology in Preclinical Drug Development is a resource for toxicologists in industry and regulatory settings, as well as directors working in contract resource organizations, who need a thorough understanding of the drug development process. Incorporating real-life case studies and examples, the book is a practical guide that outlines day-to-day activities and experiences in preclinical toxicology. This multi-contributed reference provides a detailed picture of the complex and highly interrelated activities of preclinical toxicology in both small molecules and biologics. The book discusses discovery toxicology and the international guidelines for safety evaluation, and presents traditional and nontraditional toxicology models. Chapters cover development of vaccines, oncology drugs, botanic drugs, monoclonal antibodies, and more, as well as study development and personnel, the role of imaging in preclinical evaluation, and supporting materials for IND applications. By incorporating the latest research in this area and featuring practical scenarios, this reference is a complete and actionable guide to all aspects of preclinical drug testing.

Clinical Trials

  • 1st Edition
  • October 25, 2011
  • Tom Brody
  • English
  • eBook
    9 7 8 - 0 - 1 2 - 3 9 1 9 1 3 - 7
Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines is a practical guidebook for those engaged in clinical trial design. This book details the organizations and content of clinical trials, including trial design, safety, endpoints, subgroups, HRQoL, consent forms and package inserts. It provides extensive information on both US and international regulatory guidelines and features concrete examples of study design from the medical literature. This book is intended to orient those new to clinical trial design and provide them with a better understanding of how to conduct clinical trials. It will also act as a guide for the more experienced by detailing endpoint selection and illustrating how to avoid unnecessary pitfalls. This book is a straightforward and valuable reference for all those involved in clinical trial design.

An Introduction to Pharmaceutical Sciences

  • 1st Edition
  • July 25, 2011
  • Jiben Roy
  • English
  • Paperback
    9 7 8 - 1 - 9 0 7 5 6 8 - 5 2 - 7
  • eBook
    9 7 8 - 1 - 9 0 8 8 1 8 - 0 4 - 1
This textbook is written as a unified approach to various topics, ranging from drug discovery to manufacturing, techniques and technology, regulation and marketing. The key theme of the book is pharmaceuticals - what every student of pharmaceutical sciences should know: from the active pharmaceutical ingredients to the preparation of various dosage forms along with the relevant chemistry, this book makes pharmaceuticals relevant to undergraduate students of pharmacy and pharmaceutical sciences.This book explains how a particular drug was discovered and then converted from lab-scale to manufacturing scale, to the market. It explains the motivation for drug discovery, the reaction chemistry involved, experimental difficulties, various dosage forms and the reasoning behind them, mechanism of action, quality assurance and role of regulatory agencies. After having a course based on this book, the student will be able to understand: 1) the career prospects in the pharmaceutical industry, 2) the need for interdisciplinary teamwork in science, 3) the techniques and technology involved in making pharmaceuticals starting from bulk drugs, and 4) different dosage forms and critical factors in the development of pharmaceutical formulations in relation to the principles of chemistry.A few blockbuster drugs including atorvastatin, sildanefil, ranitidine, ciprofloxacin, amoxicillin, and the longest serving drugs such as aspirin and paracetamol are discussed in detail. Finally, the book also covers the important current pharmaceutical issues like quality control, safety, counterfeiting and abuse of drugs, and future prospects for pharmaceutical industry.

Profiles of Drug Substances, Excipients and Related Methodology

  • 1st Edition
  • Volume 36
  • June 16, 2011
  • Harry G. Brittain
  • English
  • eBook
    9 7 8 - 0 - 1 2 - 3 8 7 7 0 2 - 4
Volumes in this widely revered series present comprehensive reviews of drug substances and additional materials, with critical review chapters that summarize information related to the characterization of drug substances and excipients. This organizational structure meets the needs of the pharmaceutical community and allows for the development of a timely vehicle for publishing review materials on this topic. The scope of the Profiles series encompasses review articles and database compilations that fall within one of the following six broad categories: Physical profiles of drug substances and excipients; Analytical profiles of drug substances and excipients; Drug metabolism and pharmacokinetic profiles of drug substances and excipients; Methodology related to the characterization of drug substances and excipients; Methods of chemical synthesis; and Reviews of the uses and applications for individual drug substances, classes of drug substances, or excipients.